Psilocybin Mushroom Therapy in Australia: A Guide to the New Medical Frontier
Australia has positioned itself as a world leader in psychedelic medicine. Since July 2023, the country has permitted authorised psychiatrists to prescribe psilocybin for treatment-resistant depression (TRD) . This makes Australia the first nation to regulate these substances as medicines within a national healthcare framework . Consequently, understanding how this therapy works, who can access it, and what the research shows is essential for anyone considering this innovative treatment.
What Is Psilocybin Mushroom Therapy?
Psilocybin mushroom therapy, often called psilocybin-assisted psychotherapy (PAP), is not simply taking a drug. It is a structured treatment combining the psychedelic compound with psychological support . The therapy involves several distinct phases. First, patients undergo preparation sessions with therapists to build trust and set intentions. Second, the patient takes a controlled dose of psilocybin in a comfortable setting, supported by a team of therapists. Finally, integration sessions help patients process their experience and incorporate insights into their daily lives.
The evidence for this approach is growing. Australia’s first clinical trial at Swinburne University found that most participants experienced a “clinically meaningful reduction in depression symptoms” after two 25mg psilocybin sessions . Lead researcher Professor Susan Rossell noted that the treatment offers hope to “those who may have run out of treatment options and hope” . A St Vincent’s Hospital Melbourne trial also demonstrated rapid and sustained reductions in depression and anxiety for palliative care patients .
The Legal Framework: How Access Works
The legal pathway for psilocybin therapy is strictly regulated. Only psychiatrists can prescribe it, and only for treatment-resistant depression (TRD) . The psychiatrist must hold specialist registration with the Medical Board of Australia, be a Fellow of the Royal Australian and New Zealand College of Psychiatrists (RANZCP), and obtain authorisation under the TGA’s Authorised Prescriber (AP) scheme .
To become an Authorised Prescriber, psychiatrists must develop a clinical treatment protocol and obtain approval from a registered Human Research Ethics Committee (HREC) . The treatment must be delivered in a medically supervised setting, and patients cannot take the medicine home . The TGA recommends a “therapy dyad” approach, involving the AP psychiatrist and at least one other registered health practitioner .
Recent Developments: Expanding Access
The regulatory framework continues to evolve. In May 2026, the TGA released updated recommendations following a consultation with over 80 stakeholders . The changes are designed to expand access while maintaining safety . Key updates include broadening the pool of eligible therapists to include psychotherapists and counsellors, accepting a wider range of treatment settings outside hospitals, and allowing the AP psychiatrist to be present only during drug administration rather than the full dosing day .
The TGA noted that these changes will “support workforce capacity in rural and regional Australia, address shortages, and improve culturally appropriate care” . However, safety concerns remain. Some clinicians have warned that the relaxed rules could endanger vulnerable patients without standardised training benchmarks .
Costs and Coverage
Accessing psilocybin therapy remains expensive. At the Empax Centre in Perth, a course costs about $20,000 . However, coverage is expanding. Medibank Private became the first health insurer to fund the psychotherapy component of psychedelic-assisted therapy . The Department of Veterans’ Affairs (DVA) also provides access for eligible veterans with severe PTSD and treatment-resistant depression .
Safety and Clinical Evidence
The real-world safety profile has been encouraging. According to aggregated data from the TGA, no serious adverse events have been reported under the AP scheme since December 2025 . Mental health experts emphasise that the treatment is not suitable for everyone and should only occur under medical supervision . Common side effects are mild, but cardiac issues and antidepressant interactions are contraindications .
Conclusion
Australia’s psilocybin therapy program is a pioneering step in mental health treatment. It provides a regulated pathway for patients with treatment-resistant depression to access this emerging therapy. The framework is evolving to expand access, but it remains strictly controlled and requires a rigorous process involving authorised psychiatrists, multidisciplinary therapy teams, and controlled clinical settings. For those who have exhausted other options, discussing this treatment with a General Practitioner and a suitably qualified psychiatrist is the only legal path forward.